Rutika Mehta

MD, MBBS, MPH

Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Hematology-Oncology Fellow (Class of 2017)

Background

Education and Training:

  • Topiwala National Medical College, India
  • St. Louis University School of Public Health, St. Louis, MO
  • Indiana University Purdue University, Indianapolis, IN

Residency:

  • Internal Medicine, JHU/Sinai Hospital of Baltimore, Baltimore, MD

Publications

Jasra S, Opyrchal M, Norton L, Mehta R. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clin Breast Cancer. 2016 (accepted).

Miller KD, Mehta R, Abraham J, Jain RK. Patterns of Long-Term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center. Am J Clin Oncol. 2015 Oct 15

Miller KD, Pandey M, Jain RK, Mehta R. Cancer Survivorship and Models of Survivorship Care: A Review. Am J Clin Oncol (accepted)

Gökmen­Polar Y, Liu Y, Toroni RA, Mehta R, Badve S, Rommel C, Sledge GW Jr. Investigational drug MLN0128, a novel TORC 1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat. 2012 Oct 21; 136(3):673-82

Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen­Polar Y, Kesler KA, Henley JD, Loehrer, PJ Sr, Badve S. Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol. 2012 Mar;25(3):370­7

Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K. PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci. 2011 Aug 15;124(Pt 16):2711­22

Jain RK*, Mehta R*, Dimitrov R, Larsson L, Musto P, Hodges K, Ulbright T, Hattab E, Agaram N, Idrees M, Badve S. Atypical ductal hyperplasia at 25 years­ Interobserver and Intraobserver variability. Mod Pathol. 2011 Jul;24(7):917­23 *Contributed equally to the work.

Mehta R, Jain RK, Leung S, Choo J, Neilsen T, Huntsman D, Nakshatri H, Badve S. FOXA1 is an independent prognostic marker for ER + Breast Cancer. Breast Cancer Res Treat. 2011 Apr 19. [Epub ahead of print]

Mehta R, Jain RK, Badve S. Personalized medicine: The road ahead (Review Article). Clin Breast Cancer. 2011 Mar;11(1):20­6

Jain RK, Mehta R, Nakshatri H, Idrees M, Badve S. Expression of high Forkhead box protein A1 in metastatic prostate cancer. Histopath 2011 Apr; 58(5): 766­72

Patel JB, Appaiah HN, Burnett RM, Bhat­Nakshatri P, Wang G, Mehta R, Badve S, Thompson M J, Hammond S, Steeg P, Liu Y, Nakshatri H. Control of EVI­1 Oncogene Expression in Metastatic Breast Cancer Cells Through MicroRNA miR­22. Oncogene 2011 Mar; 30 (11):1290­301

McCune K*, Mehta R*, Thorat M, Badve S, Nakshatri H. Loss of ER and FOXA1 expression in a progression model of luminal type A breast cancer: Insights from PyMT transgenic mouse model. Oncol Reports 2010 Nov; 24(5):1233­9

Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ, Badve S. WHO types A and AB thymomas: not always benign. Mod Pathol. 2010 Dec;23(12):1641­9

Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high­molecular­weight cytokeratin (34betaE12) is an independent predictor of disease­free survival in patients with triple­negative tumours of the breast. J Clin Pathol. 2010 Aug;63(8):744­7

Appaiah H, Bhat­Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H. ITF2 is a target of CXCR4 in MDA­MB­231 breast cancer cells and is associated with reduced survival in estrogen receptor­negative breast cancer. Cancer Biol Ther. Cancer Biol Ther. 2010 Sep;10(6):600­14

Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis­Filho JS. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010 Jul; 23(7): 951­960

Jain RK, Mehta R, Badve S. Conjunctival squamous cell carcinoma due to ocular prosthesis­ A case report and review of literature. Pathol Oncol Res. 2010 Dec;16(4):609­12

Gokmen­Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat M, Sanders K, Turbin D, Leung S, Huntsman D, Sledge GW Jr, Badve S. Diffrential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtype. Breast Cancer Res Treat. 2010 Nov;124(2):327­35

Resetkova E, Reis­Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in Breast Cancer – A story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010 Aug; 123(1): 97­108

Abstracts:

Book Chapter: Cancer Care in India. Global Perspectives on Cancer Incidence, Care, and Experience. ISBN 978-1-4408-2857-7.

Mehta R, Jain RK, Rhodes L, Abraham J, Miller KD. Long-term cancer survivorship care: On the radar screen? J Clin Oncol 31: 2013 (suppl). Abstract e20567

Badve SS, Goswami C, Gokmen­Polar Y, Nelson RP, Henley J, Miller N, Jain RK, Mehta RJ, Zaheer NA, Sledge GW, Li L, Kesler K, Loehrer PJ. Molecular predictors of metastases and stage of thymoma. J Clin Oncol 29: 2011(suppl). Abstr 10599

Mehta RJ, Jain RK, Gökmen­Polar Y, Badve S. In silico analysis of angiogenesis pathway as a prognostic tool in breast cancer. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2­6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstr 3489

Mehta R, Jain RK, Sojitra P, Gokmen­Polar Y, Badve S. Study of Concordance between RT­PCR and Immunohistochemical Testing of Hormone Receptor and HER2 Status in Breast Cancer Specimens. Mod Pathol. 2011 Feb; 24(1). Abstr 215

Jain RK, Mehta R, Ro JY, Nakshatri H, Cho YM, Badve S. FOXA1 a Poor Prognostic Marker in Prostate Cancer: A Validation Study. Mod Pathol. 2011 Feb; 24(1). Abstr 845

Jain RK, Mehta R, Sojitra P, Nakshatri H, Badve S. Interaction of Upstream Stimulatory Factor 2 and FOXA1 in Breast Cancer. Mod Pathol. 2011 Feb; 24(1).Abstr 178

Mehta R, Jain RK, Neilsen TO, Leung S, Choo J, Nakshatri H, Huntsman D, Badve S. FOXA1 is a Prognostic Marker in Breast Cancer : A Validation Study of 4046 Cases. Mod Pathol. 2010 Feb; 23(1): Abstr 268

Jain RK, Mehta R, Dimitrov R, Larsson L, Musto P, Hodges K, Ulbright T, Hattab E, Agaram N, Idrees M, Badve S. Atypical ductal hyperplasia at 25 years Interobserver and Intraobserver variability. Mod Pathol. 2010 Feb; 23(1): Abstr 229

Jain RK, Mehta R, Nakshatri H, Idrees M, Badve S. FOXA1 Expression Predicts Likelihood of Metastasis in Prostate Cancer. Mod Pathol. 2010 Feb; 23(1): Abstr 876

Jain RK, Thorat MA, Mehta R, GokmenPolar Y, Morimiya A, Beck S, Sweeney C, Ulbright T, Badve S. Gene expression profiles of Classical and Spermatocytic Seminoma. Mod Pathol. 2010 Feb; 23(1): Abstr 877

Badve S, Mehta R, Jain RK, Neilsen T, Leung S, Choo J, Huntsman D, Nakshatri H. Validation of FOXA1 as a Prognostic Marker in Breast Cancer in a Large Population­Based Tissue Microarray. Cancer Research (Meeting Abstract Supplement). 2009 Dec; 69(Suppl): Abstr 2130